**Non-Consolidated Financial Results (Japanese GAAP)**
**for the Fiscal Year Ended December 31, 2025**

February 10, 2026

Company Name: Chiome Bioscience Inc. Tokyo Stock Exchange
Stock Code: 4583 URL https://www.chiome.co.jp
Representative: Masamichi Koike, President & CEO
Inquiries: Arihiko Bijohira, Executive officer, Head of Corporate Administration TEL: +81-3-6383-3561
Scheduled date of the Annual General Meeting of Shareholders : March 27, 2026
Scheduled dividend payment commencement date: —
Scheduled filing date of the Securities Report : March 27, 2026
Supplementary materials prepared for the financial results : Yes
Holding of a financial results explanatory meeting : Yes (For institutional investors and securities analysts)

(Amounts of less than one million yen are rounded down)

## 1. Financial Results for the Fiscal Year Ended December 31, 2025 (January 1, 2025 to December 31, 2025)

(1) Operating Results

(% figures are the increase / (decrease) compared with the previous fiscal year)

| | Net Sales | | Operating Income | | Ordinary Income | | Net Income | |
|---|---|---|---|---|---|---|---|---|
| | Million yen | % | Million yen | % | Million yen | % | Million yen | % |
| Fiscal year ended Dec. 31, 2025 | 593 | (24.0) | (979) | — | (989) | — | (982) | — |
| Fiscal year ended Dec. 31, 2024 | 780 | 14.4 | (1,030) | — | (1,019) | — | (1,020) | — |

| | Net Income per Share | Diluted Net Income per Share | Return on Equity | Ordinary Income to Total Assets | Operating Income to Net Sales |
|---|---|---|---|---|---|
| | Yen | Yen | % | % | % |
| Fiscal year ended Dec. 31, 2025 | (14.47) | — | (65.1) | (47.1) | (165.1) |
| Fiscal year ended Dec. 31, 2024 | (17.54) | — | (66.9) | (48.3) | (132.0) |

(Reference) Equity in earnings (losses) of affiliates: Fiscal year ended Dec. 31, 2025 — million yen
Fiscal year ended Dec. 31, 2024 — million yen

Notes:
1. Despite the existence of shares with a dilutive effect, diluted net income per share is not stated because Chiome incurred a loss for each respective period.

(2) Financial Position

| | Total Assets | Net Assets | Equity Ratio | Net Assets per Share |
|---|---|---|---|---|
| | Million yen | Million yen | % | Yen |
| As of Dec. 31, 2025 | 1,727 | 1,122 | 64.1 | 16.18 |
| As of Dec. 31, 2024 | 2,468 | 1,920 | 77.4 | 28.53 |

(Reference) Equity As of Dec. 31, 2025: 1,107 million yen As of Dec. 31, 2024: 1,910 million yen

(3) Cash Flows

| | Cash Flow from Operating Activities | Cash Flow from Investing Activities | Cash Flow from Financing Activities | Cash and Cash Equivalents as of the End of the Period |
|---|---|---|---|---|
| | Million yen | Million yen | Million yen | Million yen |
| Fiscal year ended Dec. 31, 2025 | (935) | (55) | 133 | 1,205 |
| Fiscal year ended Dec. 31, 2024 | (1,000) | — | 1,738 | 2,063 |

## 2. Dividends

| | Annual Dividend | | | | | Total Dividend (Annual) | Dividend Payout Ratio | Dividends to Net Assets |
|---|---|---|---|---|---|---|---|---|
| | 1Q-End | 2Q-End | 3Q-End | FY-End | Total | | | |
| | Yen | Yen | Yen | Yen | Yen | Million yen | % | % |
| Fiscal period ended Dec. 31, 2024 | — | 0.00 | — | 0.00 | 0.00 | — | — | — |
| Fiscal year ended Dec. 31, 2025 | — | 0.00 | — | 0.00 | 0.00 | — | — | — |
| Fiscal year ending Dec. 31, 2026 (forecast) | — | 0.00 | — | 0.00 | 0.00 | | — | |

## 3. Forecast of Financial Results for the Fiscal Year Ending December 31, 2026 (January 1, 2026 to December 31, 2026)

As it is difficult to provide reasonable estimates for Drug Discovery and Development Business at present, Chiome discloses only business forecasts for Drug Discovery Support Business (net sales of ¥600 million). For details, please refer to "1. Overview of Operating Results (4) Outlook for the Fiscal Year Ending December 31, 2026" on page 5 of the attached materials.

Notes:

(1) Changes in Accounting Policies, Changes in Accounting Estimates, and Retrospective Restatements
- 1) Changes in accounting policies in line with revisions to accounting and other standards : No
- 2) Changes in accounting policies other than 1) above : No
- 3) Changes in accounting estimates : No
- 4) Retrospective restatements : No

(2) Number of Shares Issued (Common Stock)

| | | | | |
|---|---|---|---|---|
| 1) Number of shares issued as of the end of the period (including treasury stock) | As of Dec. 31, 2025 | 68,453,800 shares | As of Dec. 31, 2024 | 66,969,000 shares |
| 2) Number of treasury stock as of the end of the period | As of Dec. 31, 2025 | 12,149 shares | As of Dec. 31, 2024 | 12,149 shares |
| 3) Average number of shares for the period (cumulative total for the period) | Fiscal year ended Dec. 31, 2025 | 67,899,501 shares | Fiscal year ended Dec. 31, 2024 | 58,207,957 shares |

* This summary report on Chiome's financial statements is not subject to review procedures.

* Explanation Concerning the Proper Use of Financial Results Forecasts and Other Relevant Specific Items

1. Forward-looking statements including forecasts of financial results contained in this report are based on management's assumptions and beliefs that are determined to be reasonable in light of currently available information. Chiome cautions readers that due to a variety of factors actual results may differ materially from forecasts. For the assumptions that underpin financial results forecasts as well as other related items, please refer to "1. Overview of Operating Results (4) Outlook for the Fiscal Year Ending December 31, 2026" on page 5 of the attached materials.
2. Chiome plans to hold a financial results explanatory meeting for institutional investors and securities analysts on February 25, 2026. Plans are also in place to post a copy of the supplementary materials distributed at the meeting on Chiome's website in conjunction with disclosure to the Tokyo Stock Exchange today.

CONTENTS

1. Overview of Operating Results

(1) Overview of Operating Results in the Fiscal Year under Review

The Company operates a drug discovery business, mainly developing antibody drugs for areas with high unmet needs, utilizing its antibody generation technology and drug discovery know-how. The Company also operates a drug discovery support business that offers services such as antibody generation and protein expression/purification to pharmaceutical companies and academia.

During the period under review, the Company's business activities were as follows.

In the drug discovery business, Phase I clinical studies are underway for CBA-1535 and CBA-1205; both are in-house developed therapeutic antibodies for cancer. For CBA-1205, in addition to patients with melanoma and hepatocellular carcinoma, we decided to add patients with pediatric cancer, which had high unmet needs. Dosing to the target patients is ongoing.

For CBA-1535, a multi-specific antibody for cancer treatment, we continue the dose escalation to assess the safety in patients with solid tumors. In August 2025, we entered into a joint research agreement with NANO MRNA Co., Ltd. for the development of mRNA-encoded antibodies using our proprietary multi-specific antibody format, Tribody®. We have initiated activities aimed at entering into joint research or out-licensing agreements with pharmaceutical companies. For other drug discovery pipeline products, introductions and discussions are underway with potential out-licensing partners.

In the drug discovery support business, while focusing on maintaining strong relationships with existing major clients, we continue to promote activities to stabilize its revenue base by acquiring new clients during the period under review.

For the IDD business we launched during the year under review, which is a platform-based initiative for antibody drug discovery and development, we are in discussions with potential partner companies to establish its operational framework and have commenced new revenue-generating transactions. In the area of biosimilar business, the Company, Alfresa Holdings Corporation (Alfresa Holdings) and Kidswell Bio Corporation (Kidswell) applied for the public offering related to the Ministry of Health, Labour and Welfare's Subsidy Program, and the joint application was selected. We are making steady progress towards the development of new biosimilar products in collaboration with a fourth partner, Mycenax Biotech Inc., a Taiwan-based contract development and manufacturing organization. In addition, we have started collaborative work on cell line construction for a biosimilar with Alfresa Holdings and Kidswell. We are aiming to bring the product to market together with domestic and overseas companies as development partners. With a view of applying our expertise to drug discovery and development, and the fostering of drug discovery ventures, we have also entered into a business alliance agreement with SRD Corporation Ltd. in March 2025 and a business partnership agreement with Axcelead Drug Discovery Partners Inc. in October 2025 as part of initiatives for the IDD business. We will continue to promote a business providing consulting services to drug discovery ventures for the development of antibody drug discovery seeds.

In the IDD business, we provide solutions to address drug discovery needs for pharmaceutical companies and biotech ventures, utilizing our drug discovery expertise and technologies. We are working to improve multiple specific antibodies generation capabilities which has high drug discovery research needs to enhance our drug discovery technology. We are currently focusing on technology implementation on DoppeLib™, high-throughput bispecific antibody screening method. The profit generated in the IDD business during the period under review through biosimilar business, new drug development support, and drug discovery start-up evaluation is included in net sales of the drug discovery support business.

The Company's performance for the current fiscal year is as follows: net sales of ¥593,290 thousand (a decrease of ¥187,518 thousand year-on-year), R&D expenses amounted to ¥776,536 thousand (a decrease of ¥160,200 thousand year-on-year), operating loss of ¥979,774 thousand (operating loss of ¥1,030,869 thousand in the previous fiscal year), ordinary loss of ¥989,127 thousand (ordinary loss of ¥1,019,210 thousand in the previous fiscal year), net loss of ¥982,779 thousand (net loss of ¥1,020,776 thousand in the previous fiscal year). For R&D expenses, mainly because

the recorded amount of clinical development-related costs decreased compared to the previous year, the operating loss, ordinary loss, and quarterly net loss for the period all decreased year-on-year.

An overview of the Company's business activities by segment during the period under review is as follows.

1. Drug Discovery Business

➢ Drug Discovery Pipeline (out-licensed products)

PFKR is a therapeutic antibody candidate for autoimmune diseases in CNS area targeting CX3CR1, a G protein-coupled receptor (GPCR). The Company and the National Center of Neurology and Psychiatry are advancing a joint research program. In November 2024, we entered into an exclusive license agreement with Asahi Kasei Pharma, which is currently preparing to initiate preclinical studies.

➢ Drug Discovery Pipeline (In-house programs, out-licensing candidates)

For CBA-1205, we are conducting the second part of the Phase I clinical study in Japan to evaluate safety and efficacy in patients with specific cancer types. The target patients for the second part are patients with melanoma and hepatocellular carcinoma. Furthermore, joint research with a research institute in Europe suggested the potential efficacy of anti-DLK-1 antibodies against pediatric solid tumors, and the antibody has shown high safety from adult patients dosing results which makes administration to children possible. Therefore, we have decided to add a cohort targeting patients with pediatric cancer in August 2025. We will advance clinical development to obtain data aimed at maximizing product value and out-licensing potential, by evaluating safety and tolerability in pediatric patients, in addition to patients with melanoma and hepatocellular carcinoma. Notably, a melanoma patient enrolled in the first part has been dosed with CBA-1205 for more than 4 years and has maintained a stable disease (SD) assessment with tumor shrinkage.

A Phase I clinical study of CBA-1535 in patients with solid tumors is also underway in Japan. Currently the evaluation for the safety and tolerability of CBA-1535 as a single agent is in progress and no adverse events raising development concerns have been observed. We are conducting the clinical study with stepwise dose escalation, and the dose level is higher than originally planned. After confirming the efficacy signals as a single agent, we plan to combine CBA-1535 with a checkpoint inhibitor. We will proceed with the clinical study, keeping future out-licensing opportunities in mind utilizing the clinical data from the single agent study.

PTRY is a Tribody® antibody and is expected to add immune checkpoint inhibitory function on the T-cell engager function of CBA-1535. Its initial evaluations using animal models have shown strong anti-tumor effects. For the development of this product, we have decided to prioritize out-licensing to other pharmaceutical companies who can enter commercialization and clinical development rather than carrying out early clinical development by ourselves. This is because we can expect licensing out in pre-clinical stages, depending on the development status of CBA- 1535.

For PCDC, we are conducting out-licensing activities for PCDC, a humanized anti-CDCP1 antibody, with a focus on antibody drug conjugate (ADC) applications. Amid growing global interest in ADCs, we are promoting out- licensing activities with pharmaceutical companies that own ADC technologies.

PXLR is a humanized antibody targeting CXCL1 for cancer therapy. CXCL1 is highly expressed in cancers such as gastric and pancreatic cancers. It is a new candidate for out-licensing, and a joint research program with Osaka Metropolitan University is in progress.

We are also advancing initiatives to expand our new pipeline, including out-licensing activities for several drug discovery projects which are in exploratory stages, initiating joint collaborative research using Tribody®, our proprietary multi-specific antibody format, to create mRNA-encoded antibodies and advancing collaborative research with academic institutions.

➢ IDD Business

The Company has been promoting the creation of drug seeds and making them into intellectual property to expand our pipeline and explore out-licensing opportunities. In addition, we aim to enhance profitability through this IDD

business that utilizes our antibody drug discovery technology and know-how. We are currently focusing on promoting new collaborations with drug discovery start-up companies and pharmaceutical companies in drug discovery research and biosimilar development.

As a result of the above, results for the period under review in the drug discovery business are as follows: R&D expenses amounted to ¥776,536 thousand due to the progress of clinical development (a decrease of ¥160,200 thousand year-on-year), and segment loss of ¥776,536 thousand (segment loss of ¥813,784 thousand in the previous year).

The drug discovery support business contributes to the company's stable earnings. We provide research support by undertaking antibody production using our proprietary antibody generation platform, the ADLib® system, and protein preparation works mainly utilizing our protein purification technology to develop research support services for biopharmaceuticals, mainly for major domestic pharmaceutical companies such as Ono Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd. Our technical service capabilities are highly recognized by our client companies. During the interim period, we continued to acquire new clients including Nitto Boseki Co., Ltd. to promote the activities to stabilize its revenue base. The revenue from IDD business in the period under review, including biosimilar development, new drug development support, and drug discovery support evaluation, is recorded under drug discovery support business.

The results for the period under review in the drug discovery support business are as follows: net sales of ¥593,290 thousand (an increase of ¥15,433 thousand year-on-year), segment profit of ¥355,583 thousand (an increase of ¥45,683 thousand year-on-year) and segment profit margin of 59.9% (target 50%).

(2) Overview of Financial Position in the Fiscal Year under Review

(Assets)

Current assets at the end of the current fiscal year amounted to ¥1,546,698 thousand, a decrease of ¥790,973 thousand from the end of the previous fiscal year. This was mainly due to a decrease of ¥858,254 thousand in cash and deposits. Fixed assets amounted to ¥180,806 thousand, an increase of ¥49,621 thousand from the end of the previous fiscal year. As a result, total assets are ¥1,727,504 thousand, a decrease of ¥741,352 thousand from the end of the previous fiscal year.

(Liabilities)

Current liabilities at the end of the current fiscal year amounted to ¥374,885, a decrease of ¥118,547 thousand. This was mainly due to a decrease of ¥ 194,800 thousand in short-term borrowings. Fixed assets amounted to ¥230,554 thousand, an increase of ¥175,434 thousand from the end of the previous fiscal year. This increase was mainly due to issuance of corporate bonds. As a result, total liabilities amounted to ¥605,440 thousand, an increase of ¥56,886 thousand from the end of the previous fiscal year.

(Net assets)

Total net assets at the end of the current fiscal year amounted ¥1,122,064 thousand, a decrease of ¥798,239 thousand compared to the previous fiscal year. This was mainly due to a decrease in retained earnings resulting from the recording of a net loss for the period.

(3) Overview of Cash Flows in the Fiscal Year Under Review

The balance of cash and cash equivalents (hereinafter "funds") at the end of the current fiscal year was ¥1,205,026 thousand, a decrease of ¥858,254 thousand compared to the end of the previous fiscal year. The status of each cash flow and its main factors are as follows

(Cash flows from operating activities)

Funds used in operating activities amounted to ¥935,988 thousand. The main reason for this was recording of a net loss for the period before tax.

(Cash flows from investing activities)

Funds used in investing activities amounted to ¥55,463 thousand. This was mainly due to expenditures for the acquisition of tangible fixed assets.

(Cash flows from financing activities)

Funds acquired in financial activities amounted to ¥133,198 thousand. This was mainly due to the proceeds from the issuance of shares upon the exercise of subscription rights.

(4) Outlook for the Fiscal Year Ending December 31, 2026

In the drug discovery business, we are aiming a steady progress to complete CBA-1205 and CBA-1535 Phase I clinical studies as well as out-licensing activities for these two clinical products and pipeline products which are in non-clinical stages. In addition, we will promote collaboration with other pharmaceutical companies utilizing our proprietary bispecific antibody generation technologies and drug discovery knowledge.

Currently, the second part of CBA-1205 Clinical Phase I study is in progress, aiming to complete the registration for patients with hepatocellular carcinoma and pediatric cancer by the end of 2026. We will continue the evaluation of safety and initial efficacy for melanoma, hepatocellular carcinoma and pediatric patients, which will be a key element for future out-licensing activities. Should the efficacy of CBA-1205 be confirmed in multiple cancer types, it will facilitate the out-licensing activities. Accordingly, we will continue to promote clinical development to explore this potential. For CBA-1535, we will continue to advance the program with the aim of completing this part by the end of 2026, with a view to potential out-licensing based on the results of the first part of the study.

In the IDD business launched during the current fiscal year, we have been making progress in establishing our business infrastructure and are providing solutions to address drug discovery needs for pharmaceutical companies and biotech ventures, utilizing our drug discovery expertise and technologies in Biologics area. In addition, we will continue to work toward generating future revenues by new drug development and supporting start-up companies through business infrastructure we established in this fiscal year, utilizing DoppeLib™ which is a bi-specific antibody high-throughput screening method, and other technologies. For the biosimilar business, we will continue collaborative cell line construction work during the period under review, and we will advance initiatives aimed at development operations from fiscal year 2026 onward, as well as the acquisition of development partners.

In the drug discovery support business, we will continue to respond to the needs of our existing client companies by utilizing our technical services as well as utilizing a sales expansion framework under business alliance agreements. We will also continue to advance contract services such as antibody generation and protein preparation for securing a stable revenue base. In addition, we will work in parallel on initiatives aimed at expanding revenues derived from new drug development and biosimilar development in the IDD business and biosimilar business. We forecast net sales of ¥600 million in the drug discovery support business for the year ending December 2026.

2. Fundamental View on Selection of Accounting Standards

Chiome currently adopts Japanese GAAP as its accounting standards. With regard to adoption of International Financial Reporting Standards (IFRS) in the coming years, Chiome will look at various cases globally and make an appropriate decision.

3. Financial Statements

(1) Balance Sheets

Thousand yen

| | As of Dec. 31, 2024 | As of Dec. 31, 2025 |
|---|---|---|
| Assets | | |
| Current assets | | |
| Cash on hand and in banks | 2,063,280 | 1,205,026 |
| Accounts receivable | 51,063 | 71,996 |
| Inventories | 46,171 | 49,412 |
| Advance payment-trade | 101,992 | 135,015 |
| Prepaid expenses | 46,656 | 55,039 |
| Consumption taxes receivable | 24,425 | 29,520 |
| Other current assets | 4,081 | 686 |
| Total current assets | 2,337,672 | 1,546,698 |
| Non-current assets | | |
| Property and equipment | | |
| Machinery | 230,491 | 250,121 |
| Accumulated depreciation | (230,491) | (213,781) |
| Machinery, net | 0 | 36,340 |
| Tools and equipment | 82,364 | 79,857 |
| Accumulated depreciation | (82,364) | (79,857) |
| Tools and equipment, net | 0 | 0 |
| Total property and equipment | 0 | 36,340 |
| Investments and other assets | | |
| Lease deposits and others | 112,809 | 128,191 |
| Long-term prepaid expenses | 18,375 | 16,274 |
| Other, net | 0 | 0 |
| Total investments and other assets | 131,184 | 144,465 |
| Total non-current assets | 131,185 | 180,806 |
| Total assets | 2,468,857 | 1,727,504 |

Thousand yen

| | As of Dec. 31, 2024 | As of Dec. 31, 2025 |
|---|---|---|
| Liabilities | | |
| Current liabilities | | |
| Accounts payable, trade | 27,196 | 37,442 |
| Short-term borrowings | 281,500 | 86,700 |
| Accounts payable, other | 138,103 | 82,517 |
| Accrued expenses | 29,557 | 14,555 |
| Income taxes payable | 2,531 | 12,553 |
| Contract liabilities | — | 130,329 |
| Deposits received | 14,543 | 10,787 |
| Total liabilities | 493,432 | 374,885 |
| Non-current liabilities | | |
| Asset retirement obligations | 55,120 | 55,554 |
| Bonds payable | — | 175,000 |
| Total non-current liabilities | 55,120 | 230,554 |
| Total liabilities | 548,553 | 605,440 |
| Net assets | | |
| Shareholders' equity | | |
| Capital stock | 995,525 | 1,085,523 |
| Capital reserve | | |
| Legal Capital reserve | 1,935,799 | 2,025,797 |
| Total capital reserve | 1,935,799 | 2,025,797 |
| Retained earnings | | |
| Other retained earnings | | |
| Retained earnings brought forward | (1,020,776) | (2,003,555) |
| Total retained earnings | (1,020,776) | (2,003,555) |
| Treasury stock | (292) | (292) |
| Total shareholders' equity | 1,910,255 | 1,107,473 |
| Subscription rights to shares | 10,048 | 14,591 |
| Total net assets | 1,920,303 | 1,122,064 |
| Total liabilities and net assets | 2,468,857 | 1,727,504 |

(2) Statements of Income

Thousand yen

| | Fiscal Year Ended Dec. 31, 2024 (Jan. 1, 2024 to Dec. 31, 2024) | Fiscal Year Ended Dec. 31, 2025 (Jan. 1, 2025 to Dec. 31, 2025) |
|---|---|---|
| Net sales | 780,809 | 593,290 |
| Cost of sales | 347,957 | 237,707 |
| Gross profit | 432,851 | 355,583 |
| Selling, general and administrative expenses | | |
| Research and development expenses | 936,737 | 776,536 |
| Other, net | 526,984 | 558,821 |
| Total selling, general and administrative expenses | 1,463,721 | 1,335,358 |
| Operating loss | (1,030,869) | △979,774 |
| Non-operating income | | |
| Interest income | 215 | 2,458 |
| Foreign exchange gains | 919 | ― |
| Subsidy income | 28,011 | ― |
| Other, net | 845 | 142 |
| Total non-operating income | 29,991 | 2,601 |
| Non-operating expenses | | |
| Interest expenses | 2,865 | 3,155 |
| Share issuance cost | 6,572 | 1,635 |
| Subscription rights issuance cost | 8,861 | 7,027 |
| Foreign exchange losses | ― | 135 |
| Other, net | 32 | 0 |
| Total non-operating expenses | 18,331 | 11,953 |
| Ordinary loss | (1,019,210) | (989,127) |
| Extraordinary income | | |
| Gain on reversal of subscription rights to shares | 1,674 | 9,588 |
| Total extraordinary income | 1,674 | 9,588 |
| Loss before income taxes | (1,017,536) | (979,539) |
| Income taxes-current | 3,240 | 3,240 |
| Total income taxes | 3,240 | 3,240 |
| Net loss | (1,020,776) | (982,779) |

【Details of Cost of Sales】

| Category | note | Fiscal Year Ended Dec. 31, 2024 (Jan. 1, 2024 to Dec. 31, 2024) Amount (Thousand yen) | Proportion of cost of sales (%) | Fiscal Year Ended Dec. 31, 2025 (Jan. 1, 2025 to Dec. 31, 2025) Amount (Thousand yen) | Proportion of cost of sales (%) |
|---|---|---|---|---|---|
| I Cost of materials | | 117,980 | 33.9 | 112,744 | 47.4 |
| II Labor costs | | 76,755 | 22.0 | 68,723 | 28.9 |
| III Expenses | * 1 | 153,522 | 44.1 | 56,603 | 23.7 |
| Total manufacturing costs | | 348,258 | 100.0 | 238,071 | 100.0 |
| Opening balance of work-in-progress under inventories | | 1,644 | | 1,944 | |
| Total | | 349,902 | | 240,016 | |
| Closing balance of work-in-progress under inventories | | 1,944 | | 2,309 | |
| Cost of sales | | 347,957 | | 237,707 | |

Method of calculating cost of sales: Cost of sales is calculated based on the specific identification method by project.

(Note)*1 The following are major items.

Thousand yen

| | Fiscal Year Ended Dec. 31, 2024 (Jan. 1, 2024 to Dec. 31, 2024) | Fiscal Year Ended Dec. 31, 2025 (Jan. 1, 2025 to Dec. 31, 2025) |
|---|---|---|
| Royalties paid | 95,132 | 11,883 |
| Outsourcing expenses | 5,191 | 3,827 |
| Other expenses | 53,198 | 40,893 |

(3) Statements of Changes in Net Assets

The Fiscal Period Ended December 31, 2024 (January 1, 2024 to December 31, 2024)

Thousand yen

| | | Shareholders' Equity | | | | |
|---|---|---|---|---|---|---|
| | Capital Stock | | Capital Reserve | | Retained Earnings | |
| | | Legal Capital reserve | Other capital surplus | Total capital reserve | Other retained earnings<br>Retained earnings brought forward | Total retained earnings |
| Balance as of the beginning of the period | 2,388,422 | 3,988,202 | — | 3,988,202 | (5,236,350) | (5,236,350) |
| Changes during the period | | | | | | |
| Issuance of new stock | 895,525 | 895,525 | | 895,525 | | — |
| Capital reduction | (2,288,422) | (2,947,928) | 5,236,350 | 2,288,422 | | — |
| Deficit disposition | | | (5,236,350) | (5,236,350) | 5,236,350 | 5,236,350 |
| Net loss | | | | — | (1,020,776) | (1,020,776) |
| Net changes of items other than shareholders' equity | — | — | — | — | — | — |
| Total changes during the period | (1,392,897) | (2,052,403) | — | (2,052,403) | 4,215,574 | 4,215,574 |
| Balance as of the end of the period | 995,525 | 1,935,799 | — | 1,935,799 | (1,020,776) | (1,020,776) |

| | Shareholders' Equity | | Subscription rights to shares | Total Net Assets |
|---|---|---|---|---|
| | Treasury Stock | Total Shareholders' Equity | | |
| Balance as of the beginning of the period | (292) | 1,139,981 | 17,741 | 1,157,723 |
| Changes during the period | | | | |
| Issuance of new stock | | 1,791,050 | | 1,791,050 |
| Capital reduction | | — | | — |
| Deficit disposition | | — | | — |
| Net loss | | (1,020,776) | | (1,020,776) |
| Net changes of items other than shareholders' equity | | — | (7,693) | (7,693) |
| Total changes during the period | — | 770,274 | (7,693) | 762,580 |
| Balance as of the end of the period | (292) | 1,910,255 | 10,048 | 1,920,303 |

The Fiscal Period Ended December 31, 2025 (January 1, 2025 to December 31, 2025)

Thousand yen

| | Shareholders' Equity | | | | |
|---|---|---|---|---|---|
| | Capital Stock | Capital Reserve | | Retained Earnings | |
| | | Legal Capital reserve | Total capital reserve | Other retained earnings<br>Retained earnings brought forward | Total retained earnings |
| Balance as of the beginning of the period | 995,525 | 1,935,799 | 1,935,799 | △1,020,776 | △1,020,776 |
| Changes during the period | | | | | |
| Issuance of new stock | 89,998 | 89,998 | 89,998 | | — |
| Net loss | | | — | △982,779 | △982,779 |
| Net changes of items other than shareholders' equity | — | — | — | — | — |
| Total changes during the period | 89,998 | 89,998 | 89,998 | △982,779 | △982,779 |
| Balance as of the end of the period | 1,085,523 | 2,025,797 | 2,025,797 | △2,003,555 | △2,003,555 |

| | Shareholders' Equity | | Subscription rights to shares | Total Net Assets |
|---|---|---|---|---|
| | Treasury Stock | Total Shareholders' Equity | | |
| Balance as of the beginning of the period | △292 | 1,910,255 | 10,048 | 1,920,303 |
| Changes during the period | | | | |
| Issuance of new stock | | 179,997 | | 179,997 |
| Net loss | | △982,779 | | △982,779 |
| Net changes of items other than shareholders' equity | | — | 4,543 | 4,543 |
| Total changes during the period | — | △802,782 | 4,543 | △798,239 |
| Balance as of the end of the period | △292 | 1,107,473 | 14,591 | 1,122,064 |

(4) Statements of Cash Flows

Thousand yen

| | Fiscal Year Ended Dec. 31, 2024 (Jan. 1, 2024 to Dec. 31, 2024) | Fiscal Year Ended Dec. 31, 2025 (Jan. 1, 2025 to Dec. 31, 2025) |
|---|---|---|
| Cash flows from operating activities | | |
| Loss before income taxes | (1,017,536) | (979,539) |
| Depreciation and amortization | 1,166 | 3,740 |
| Subsidy income | (28,011) | — |
| Decrease (increase) in notes and accounts receivable-trade | 32,130 | (20,933) |
| Decrease (increase) in inventories | 17,936 | (3,241) |
| Decrease (increase) in advance payments | (15,195) | (33,022) |
| Decrease (increase) in consumption taxes refund receivable | (2,179) | (5,095) |
| Increase (decrease) in notes and accounts payable-trade | (10,538) | 10,245 |
| Increase Decrease in contract liabilities | — | 130,329 |
| Increase (decrease) in accounts payable-other | 20,763 | (55,585) |
| Increase (decrease) in accrued expenses | 3,969 | (15,002) |
| Other, net | 4,488 | 35,721 |
| Subtotal | (993,005) | (932,382) |
| Interest income received | 182 | 2,081 |
| Interest paid | (2,865) | (3,155) |
| Income taxes paid | (5,010) | (3,240) |
| Income taxes refund | 2 | 708 |
| Net cash used in operating activities | (1,000,695) | (935,988) |
| Cash flows from investing activities | | |
| Purchase of property plant and equipment | — | (40,080) |
| Payments for lease and guarantee deposits | — | (15,383) |
| Net cash used in investing activities | — | (55,463) |
| Cash flows from financing activities | | |
| Increase decrease in short term loans payable | (9,500) | (194,800) |
| Proceeds From Issuance of Bonds | 250,000 | 200,000 |
| Redemption of Bonds | (250,000) | (25,000) |
| Proceeds from issuance of common shares | 1,749,912 | 145,055 |
| Proceeds from issuance of subscription rights to shares | — | 14,971 |
| Proceeds from issuance of subscription rights to shares | (582) | (7,027) |
| Payments for purchase of treasury subscription right to shares | (1,408) | — |
| Net cash provided by (used in) financing activities | 1,738,421 | 133,198 |
| Net decrease in cash and cash equivalents | 737,725 | (858,254) |
| Cash and cash equivalents as of the beginning of the year | 1,325,554 | 2,063,280 |
| Cash and cash equivalents as of the end of the year | 2,063,280 | 1,205,026 |

(5) Notes to Financial Statements

(Notes regarding going concern assumptions)

No item to report.

(Equity in earnings or losses)

Not applicable as Chiome does not have non-consolidated subsidiaries and affiliates.

(Segment information)

i. Overview of reportable segments

The business segments for reporting purposes are the business units for which Chiome is able to obtain respective financial information separately in order for its Board of Directors to conduct periodic assessments and reviews to determine the proper allocation of management resources and to evaluate business results.

With the major business territory focused on the antibody research phase, covering investigation research, research for drug discovery, and early clinical development, Chiome puts forward comprehensive global strategies and runs business activities.

Chiome has two reportable segments, Drug Discovery and Development Business and Drug Discovery Support Business. Under Drug Discovery and Development Business, Chiome discover and develop novel antibody drugs in therapeutic areas where high unmet medical needs exist. The drug candidates will be out-licensed to pharmaceutical company under appropriate financial conditions such like upfront, milestone, and royalty payments etc. Under Drug Discovery Support Business, Chiome provides “fee-for-service” to pharmaceutical and diagnostics company, and academia to support their research works. Main line of this business is to generate a monoclonal antibody for their targets by our proprietary platform, and to express, culture, and purify proteins including antigen and antibody.

ii. Method for computing the amounts of operating revenue, income or loss, assets, and liabilities as well as other items for reportable segments:

The accounting method for reportable segments is pursuant to the accounting policies adopted for the preparation of financial statements.

iii. Information relating to the amounts of operating revenue, income or loss, assets, and liabilities as well as other items for reportable segments:

The Fiscal Year Ended December 31, 2024 (January 1, 2024 to December 31, 2024)

(Thousand yen)

| | Reportable Segments | | Total | Adjustments (Note 1) | Amount Recorded on the Balance Sheet (Note 2) |
|---|---|---|---|---|---|
| | Drug Discovery and Development Business | Drug Discovery Support Business | | | |
| Net sales | | | | | |
| Goods or services transferred at one point of time | 202,952 | 164,763 | 367,716 | － | 367,716 |
| Goods or services transferred over a period of time | － | 413,093 | 413,093 | － | 413,093 |
| Revenue from contracts with customers | 202,952 | 577,857 | 780,809 | － | 780,809 |
| Sales to external customers | 202,952 | 577,857 | 780,809 | － | 780,809 |
| Internal sales or exchange between segments | － | － | － | － | － |
| Total | 202,952 | 577,857 | 780,809 | － | 780,809 |
| Segment income (loss) | (813,784) | 309,899 | (503,885) | (526,984) | (1,030,869) |
| Segment assets | － | － | － | 2,468,857 | 2,468,857 |

Notes:

1. Details regarding adjustments are presented as follows:
   (1) Adjustments to segment income (loss) are selling, general and administrative expenses that relate to areas other than research and development.
   (2) Segment assets are not allocated between segments because all assets of the Company are unified in their generation of cash flows and apply to multiple antibody generation technologies. Accordingly, the amount of total assets recorded on the balance sheet is presented as the adjustment balance.
2. The total amount of segment income (loss) is reconciled with operating loss recorded in the statement of income.

The Fiscal Year Ended December 31, 2025 (January 1, 2025 to December 31, 2025)

(Thousand yen)

| | Reportable Segments | | Total | Adjustments (Note 1) | Amount Recorded on the Balance Sheet (Note 2) |
|---|---|---|---|---|---|
| | Drug Discovery and Development Business | Drug Discovery Support Business | | | |
| Net sales | | | | | |
| Goods or services transferred at one point of time | — | 190,181 | 190,181 | — | 190,181 |
| Goods or services transferred over a period of time | — | 403,109 | 403,109 | — | 403,109 |
| Revenue from contracts with customers | — | 593,290 | 593,290 | — | 593,290 |
| Sales to external customers | — | 593,290 | 593,290 | — | 593,290 |
| Internal sales or exchange between segments | — | — | — | — | — |
| Total | — | 593,290 | 593,290 | — | 593,290 |
| Segment income (loss) | △776,536 | 355,583 | △420,952 | △558,821 | △979,774 |
| Segment assets | — | — | — | 1,727,504 | 1,727,504 |

Notes:

1. Details regarding adjustments are presented as follows:
   (1) Adjustments to segment income (loss) are selling, general and administrative expenses that relate to areas other than research and development.
   (2) Segment assets are not allocated between segments because all assets of the Company are unified in their generation of cash flows and apply to multiple antibody generation technologies. Accordingly, the amount of total assets recorded on the balance sheet is presented as the adjustment balance.
2. The total amount of segment income (loss) is reconciled with operating loss recorded in the statement of income.

(Per share information)

(Yen)

| | Fiscal Year Ended Dec. 31, 2024 (Jan. 1, 2024 to Dec. 31, 2024) | Fiscal Year Ended Dec. 31, 2025 (Jan. 1, 2025 to Dec. 31, 2025) |
|---|---|---|
| Net assets per share | 28.53 | 16.18 |
| Net loss per share | (17.54) | (14.47) |

Notes:

1. Details regarding diluted net income per share are not provided despite the existence of shares with the potential to have a dilutive effect. This is because of the net loss for the period.
2. The basis for calculations are presented as follows:
   (1) Net assets per share

(Thousand yen unless otherwise stated)

| | As of Dec. 31, 2024 | As of Dec. 31, 2025 |
|---|---|---|
| Total net assets | 1,920,303 | 1,122,064 |
| Amount deducted from total net assets | 10,048 | 14,591 |
| (New subscription rights to shares) | (10,048) | (14,591) |
| Net assets allocated to capital stock | 1,910,255 | 1,107,473 |
| Number of shares of capital stock used to calculate net assets per share (shares) | 66,956,851 | 68,441,651 |

   (2) Net loss per share

(Thousand yen unless otherwise stated)

| | Fiscal Year Ended Dec. 31, 2024 (Jan. 1, 2024 to Dec. 31, 2024) | Fiscal Year Ended Dec. 31, 2025 (Jan. 1, 2025 to Dec. 31, 2025) |
|---|---|---|
| Net loss | (1,020,776) | (982,779) |
| Amount not attributable to shareholders of capital stock | — | — |
| Net loss allocated to capital stock | (1,020,776) | (982,779) |
| Average number of shares for the period (shares) | 58,207,957 | 67,899,501 |
| Details of dilutive shares not included in calculations relating to net income per diluted share because there was no dilutive effect | New subscription rights to shares:3 types<br>Number of subscription rights to shares: 10,540 | New subscription rights to shares:2 types<br>Number of subscription rights to shares: 132,700 |

(Important subsequent events)

1. Capital Increase Attributed to the Exercise of Subscription Rights to Shares

After the end of the current fiscal year and up to January 31, 2026, a portion of the 23rd stock acquisition rights were exercised. The summary of the exercised stock acquisition rights is as follows.

(1) Type and number of shares issued: Common stock, 1,000,000 shares

(2) Increased capital stock: ¥51,630 thousand

(3) Increased legal capital reserve: ¥51,630 thousand

As a result, as of January 31, 2026, the total number of the common stock issued is 69,453,800 shares. The capital stock and capital reserve are ¥1,137,153 thousand and ¥2,077,427 thousand respectively.

2. Early Redemption of Corporate Bonds

After the end of the current fiscal year and up to January 31, 2026, a portion of the Second Unsecured Corporate Bonds was early redeemed in accordance with the redemption provisions thereof. The summary of the corporate bonds are as follows.

(1) Bonds subject to early redemption

The second unsecured corporate bonds of Chiome Bioscience Inc.

(2) Total amount of early redemption

¥ 115,000 thousand

(3) Face value per bond

¥ 5,000 thousand

(4) Redemption price

100% of the face value (¥ 100 per ¥ 100)

(5) Reason for early redemption

Exercise of the 23rd series of stock acquisition rights

(6) Source of funds for redemption

Proceeds from the exercise of the 23rd series of stock acquisition rights

(7) Annual reduction in interest expense resulting from the early redemption

None (the bonds bear no interest)

[Reference]

· Original maturity date: December 14, 2027